Episode
From Gila Monster to GLP-1 Revolution
- Published
- Feb 26, 2026
- Duration seconds
- 791
- Processing state
not_requested- Canonical source
- https://forku.com/episode/from-gila-monster-to-glp-1-revolution
Actions
POST https://stenobird.com/v1/public/podcasts/fork-u-with-dr-terry-simpson-940256/episodes/from-gila-monster-to-glp-1-revolution/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/fork-u-with-dr-terry-simpson-940256/from-gila-monster-to-glp-1-revolution.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Meanwhile, in a Laboratory In 1990, researchers isolated a peptide from Gila monster venom. Two years later, work from the Bronx VA Medical Center described exendin-4, a molecule that resembled human GLP-1 but lasted far longer in circulation. Human GLP-1 survives only minutes before the body breaks it down. Exendin-4 resisted that breakdown. That difference changed everything. Soon afterward, the first GLP-1 receptor agonist reached patients under the brand name Byetta . At the time, physicians used it to treat diabetes. No one called it a weight-loss drug. No one predicted it would reshape obesity medicine. And yet, the foundation was already in place. While I Was Operating At the Phoenix Indian Medical Center, I performed weight loss surgery in a population with some of the highest rates of type 2 diabetes in the world. Researchers there studied metabolism intensely. The “thrifty gene” hypothesis gained traction in that environment. Scientists asked whether efficient energy storage, once protective in scarcity, became harmful in abundance. At the same time, I watched something remarkable in the operating room. After gastric bypass, patients’ blood sugars often improved within days, before meaningful weight loss occurred. Hormones were shifting. Physiology was driving outcomes. Meanwhile, GLP-1 drugs evolved. Researchers lengthened their half-lives. Chemists modified their structures so they bound albumin and stayed active for days rather than minutes. Clinical trials expanded. Safety data accumulated. Eventually, semaglutide showed average weight loss approaching fifteen percent of body weight in obesity trials. Then tirzepatide, now marketed as Zepbound for obesity, exceeded 20 percent weight reduction in higher-dose studies. In addition, cardiovascular outcome tri…